In contrast to previous meta-analyses evaluating the effects of SGLT2-i in type 2 diabetes, we only included trials, which used the recommended maximum daily doses of the SGLT2-i [24–36] as we expect these dosages to be the most widely used in the clinic [4–10]. Here, SLC5A2 is linked to type 2 diabetes mellitus.